For Physicians

If you have a HSCT recipient with an asymptomatic CMV infection, the AURORA clinical research study may be right for them.

AURORA is a clinical research study designed to explore an investigational drug—maribavir—in hematopoietic stem cell transplant (HSCT) recipients with a CMV infection that is not showing symptoms (is asymptomatic).

The main goal of the 22-week study is to see if maribavir works to clear CMV infections from the blood in HSCT recipients with an asymptomatic CMV infection. Participants will be randomized to receive either maribavir (the investigational drug) or valganciclovir for 8 weeks. Valganciclovir is an anti-CMV treatment that is most often used as a first-line treatment for CMV infection. The investigational drug is given as an oral pill.

Learn more about the initial inclusion criteria for this clinical research study.

All fields are required.


Your contact information will only be used for study-related communications and will not be shared with anyone outside of the study.